These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

637 related items for PubMed ID: 28342113

  • 1. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P, Woolacott N, Biswas M, Mebrahtu T, Harden M, Hodgson R.
    Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
    [Abstract] [Full Text] [Related]

  • 2. Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Claxton L, O'Connor J, Woolacott N, Wright K, Hodgson R.
    Pharmacoeconomics; 2019 May; 37(5):645-654. PubMed ID: 30298279
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence.
    Wade R, Hodgson R, Biswas M, Harden M, Woolacott N.
    Pharmacoeconomics; 2017 Feb; 35(2):203-213. PubMed ID: 27592020
    [Abstract] [Full Text] [Related]

  • 6. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B, Pandor A, Stevenson M, Hamilton J, Chambers D, Clowes M, Graham J, Kumar MS.
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [Abstract] [Full Text] [Related]

  • 7. Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S, Squires H, Hock E, Kaltenthaler E, Rawdin A, Alifrangis C.
    Pharmacoeconomics; 2019 Sep; 37(9):1073-1080. PubMed ID: 30547369
    [Abstract] [Full Text] [Related]

  • 8. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J, Al MJ.
    Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L, Bermejo I, Ren S, Martyn-St James M, Wong R, Scott DL, Young A, Stevenson M.
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [Abstract] [Full Text] [Related]

  • 12. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M, Pandor A, Hamilton J, Stevens J, Rowntree C, Martyn-St James M, Rawdin A, Wong R.
    Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
    [Abstract] [Full Text] [Related]

  • 13. Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Rose M, Shepherd J, Harris P, Pickett K, Lord J.
    Pharmacoeconomics; 2018 Nov; 36(11):1299-1308. PubMed ID: 29691773
    [Abstract] [Full Text] [Related]

  • 14. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M, Kaltenthaler E, Ingram JR, Collier F, Ghazavi M.
    Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.
    Pennington B, Ren S, Barton S, Bacelar M, Edwards SJ.
    Pharmacoeconomics; 2019 Aug; 37(8):985-993. PubMed ID: 30465228
    [Abstract] [Full Text] [Related]

  • 17. The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Cox E, Wade R, Peron M, Dietz KC, Eastwood A, Palmer S, Griffin S.
    Pharmacoeconomics; 2019 Sep; 37(9):1081-1091. PubMed ID: 30887470
    [Abstract] [Full Text] [Related]

  • 18. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I, Ren S, Simpson E, Clowes M, Scott DL, Young A, Stevenson M.
    Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
    [Abstract] [Full Text] [Related]

  • 19. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M.
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [Abstract] [Full Text] [Related]

  • 20. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
    Thielen FW, Büyükkaramikli NC, Riemsma R, Fayter D, Armstrong N, Wei CY, Huertas Carrera V, Misso K, Worthy G, Kleijnen J, Corro Ramos I.
    Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.